EP1307455B1 - Inhibitors of alpha-l beta-2 mediated cell adhesion - Google Patents
Inhibitors of alpha-l beta-2 mediated cell adhesion Download PDFInfo
- Publication number
- EP1307455B1 EP1307455B1 EP00976625A EP00976625A EP1307455B1 EP 1307455 B1 EP1307455 B1 EP 1307455B1 EP 00976625 A EP00976625 A EP 00976625A EP 00976625 A EP00976625 A EP 00976625A EP 1307455 B1 EP1307455 B1 EP 1307455B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- halogen
- alkyl
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C*=C(C=C(*)*=C(C)*)NN Chemical compound C*=C(C=C(*)*=C(C)*)NN 0.000 description 8
- NJGBNLHJRLPXTC-AKYMPMEGSA-N C[C@@H](C(O)=O)NC(c(c(Cl)cc(N(C(C1(Cc(cc2)ccc2Br)N2CCC1)=O)C2=O)c1)c1Cl)=O Chemical compound C[C@@H](C(O)=O)NC(c(c(Cl)cc(N(C(C1(Cc(cc2)ccc2Br)N2CCC1)=O)C2=O)c1)c1Cl)=O NJGBNLHJRLPXTC-AKYMPMEGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK00976625T DK1307455T3 (da) | 1999-10-20 | 2000-10-19 | Inhibitorer af alpha-L-beta-2-medieret celleadhæsion |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16062999P | 1999-10-20 | 1999-10-20 | |
US160629P | 1999-10-20 | ||
US20984700P | 2000-06-07 | 2000-06-07 | |
US209847P | 2000-06-07 | ||
PCT/US2000/029273 WO2001030781A2 (en) | 1999-10-20 | 2000-10-19 | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1307455A2 EP1307455A2 (en) | 2003-05-07 |
EP1307455B1 true EP1307455B1 (en) | 2005-04-06 |
Family
ID=26857065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00976625A Expired - Lifetime EP1307455B1 (en) | 1999-10-20 | 2000-10-19 | Inhibitors of alpha-l beta-2 mediated cell adhesion |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1307455B1 (zh) |
JP (1) | JP3943394B2 (zh) |
KR (1) | KR100496940B1 (zh) |
CN (2) | CN1332961C (zh) |
AT (1) | ATE292634T1 (zh) |
AU (1) | AU778757B2 (zh) |
BR (1) | BR0014651A (zh) |
CA (1) | CA2388639C (zh) |
DE (1) | DE60019347T2 (zh) |
ES (1) | ES2240201T3 (zh) |
HK (1) | HK1053473A1 (zh) |
IL (2) | IL148932A0 (zh) |
MX (1) | MXPA02003977A (zh) |
NZ (1) | NZ518369A (zh) |
PT (1) | PT1307455E (zh) |
WO (1) | WO2001030781A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2994454A4 (en) * | 2013-12-09 | 2016-12-21 | Unichem Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF (3R, 4R) - (1-BENZYL-4-METHYLPIPERIDIN-3YL) -METHYLAMINE |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030781A2 (en) * | 1999-10-20 | 2001-05-03 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
AU2001281995A1 (en) * | 2000-07-21 | 2002-02-05 | Lion Bioscience Ag | Bicyclic hydantoin derivatives and combinatorial libraries thereof |
WO2002044181A1 (en) | 2000-12-01 | 2002-06-06 | Bristol-Myers Squibb Company | Hydantoin compounds useful as anti-inflammatory agents |
WO2002092606A1 (fr) * | 2001-05-15 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Derives d'imidazolidine fusionnes, leur procede de preparation et d'utilisation |
WO2003011824A1 (en) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
TW200303200A (en) * | 2002-02-07 | 2003-09-01 | Tanabe Seiyaku Co | Inhibitors of α L β 2 integrin mediated cell adhesion |
TW200407324A (en) * | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
JP4617449B2 (ja) | 2002-07-11 | 2011-01-26 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | 抗菌活性を有するn−ヒドロキシアミド誘導体 |
US6974815B2 (en) | 2002-10-11 | 2005-12-13 | Bristol-Myers Squibb Company | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
EP1567487A4 (en) * | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
US7186725B2 (en) * | 2003-01-03 | 2007-03-06 | Genzyme Corporation | Anti-inflammatory compositions and methods |
EP2374804A1 (en) * | 2003-04-22 | 2011-10-12 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7199125B2 (en) | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
TW200616634A (en) | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
US7186727B2 (en) | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
KR20080014775A (ko) * | 2005-05-13 | 2008-02-14 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 다환 화합물 및 그의 사용 방법 |
CA2624488A1 (en) * | 2005-10-06 | 2007-04-12 | Novartis Ag | Tetrahydro-pyrrolizinone compounds as lfa-i mediators |
ATE473741T1 (de) | 2006-02-10 | 2010-07-15 | Janssen Pharmaceutica Nv | Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren |
WO2008007664A1 (fr) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique bicycique et son utilisation |
DK2225238T3 (en) | 2007-11-29 | 2014-11-24 | Boehringer Ingelheim Int | Derivatives of 6,7-dihydro-5H-imidazoý1,2- imidazol-3-carboxylic acid amides. |
MX2011012717A (es) | 2009-06-02 | 2011-12-14 | Boehringer Ingelheim Int | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazo l-3-carboxilico. |
US8481750B2 (en) | 2009-06-02 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides |
US9586885B2 (en) * | 2011-07-22 | 2017-03-07 | Venantius Limited | Compounds for use in the treatment of inflammatory bowel disease |
CN106588926B (zh) * | 2016-12-28 | 2018-10-09 | 华东师范大学 | 一种2,7-二氮杂[3,2,1]二环辛烷及其衍生物及其合成方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3555876B2 (ja) * | 1997-08-22 | 2004-08-18 | エフ.ホフマン−ラ ロシュ アーゲー | N−アロイルフェニルアラニン誘導体 |
WO2001030781A2 (en) * | 1999-10-20 | 2001-05-03 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
-
2000
- 2000-10-19 WO PCT/US2000/029273 patent/WO2001030781A2/en active IP Right Grant
- 2000-10-19 MX MXPA02003977A patent/MXPA02003977A/es active IP Right Grant
- 2000-10-19 ES ES00976625T patent/ES2240201T3/es not_active Expired - Lifetime
- 2000-10-19 KR KR10-2002-7004808A patent/KR100496940B1/ko not_active IP Right Cessation
- 2000-10-19 IL IL14893200A patent/IL148932A0/xx active IP Right Grant
- 2000-10-19 AU AU14370/01A patent/AU778757B2/en not_active Ceased
- 2000-10-19 AT AT00976625T patent/ATE292634T1/de not_active IP Right Cessation
- 2000-10-19 NZ NZ518369A patent/NZ518369A/en unknown
- 2000-10-19 EP EP00976625A patent/EP1307455B1/en not_active Expired - Lifetime
- 2000-10-19 BR BR0014651-0A patent/BR0014651A/pt not_active Application Discontinuation
- 2000-10-19 JP JP2001533134A patent/JP3943394B2/ja not_active Expired - Fee Related
- 2000-10-19 DE DE60019347T patent/DE60019347T2/de not_active Expired - Lifetime
- 2000-10-19 CA CA002388639A patent/CA2388639C/en not_active Expired - Fee Related
- 2000-10-19 PT PT00976625T patent/PT1307455E/pt unknown
- 2000-10-19 CN CNB2004100963975A patent/CN1332961C/zh not_active Expired - Fee Related
- 2000-10-19 CN CNB008145814A patent/CN1185232C/zh not_active Expired - Fee Related
-
2002
- 2002-03-27 IL IL148932A patent/IL148932A/en not_active IP Right Cessation
-
2003
- 2003-08-14 HK HK03105854A patent/HK1053473A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2994454A4 (en) * | 2013-12-09 | 2016-12-21 | Unichem Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF (3R, 4R) - (1-BENZYL-4-METHYLPIPERIDIN-3YL) -METHYLAMINE |
Also Published As
Publication number | Publication date |
---|---|
KR20020068523A (ko) | 2002-08-27 |
CA2388639A1 (en) | 2001-05-03 |
WO2001030781A3 (en) | 2001-11-22 |
ES2240201T3 (es) | 2005-10-16 |
CN1185232C (zh) | 2005-01-19 |
CA2388639C (en) | 2007-07-17 |
JP3943394B2 (ja) | 2007-07-11 |
EP1307455A2 (en) | 2003-05-07 |
ATE292634T1 (de) | 2005-04-15 |
HK1053473A1 (en) | 2003-10-24 |
MXPA02003977A (es) | 2003-09-25 |
IL148932A0 (en) | 2002-09-12 |
JP2003512468A (ja) | 2003-04-02 |
PT1307455E (pt) | 2005-06-30 |
AU1437001A (en) | 2001-05-08 |
DE60019347T2 (de) | 2006-03-09 |
IL148932A (en) | 2006-12-31 |
NZ518369A (en) | 2003-09-26 |
BR0014651A (pt) | 2002-06-18 |
DE60019347D1 (de) | 2005-05-12 |
CN1651431A (zh) | 2005-08-10 |
KR100496940B1 (ko) | 2005-06-23 |
CN1332961C (zh) | 2007-08-22 |
AU778757B2 (en) | 2004-12-16 |
WO2001030781A2 (en) | 2001-05-03 |
CN1382143A (zh) | 2002-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1307455B1 (en) | Inhibitors of alpha-l beta-2 mediated cell adhesion | |
US7342012B2 (en) | Inhibitors of αLβ2 mediated cell adhesion | |
RU2686117C1 (ru) | Конденсированные производные имидазола и пиразола в качестве модуляторов активности tnf | |
AU2009231714B2 (en) | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | |
US6670357B2 (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | |
RU2696275C1 (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
AU2005251891A1 (en) | Octahydro-pyrrolo[3,4-C] derivatives and their use as antiviral compounds | |
AU2003292828A1 (en) | Diamine derivatives | |
RU2683940C1 (ru) | Производные имидазотиазола в качестве модуляторов активности tnf | |
US6710064B2 (en) | Hydantoin compounds useful as anti-inflammatory agents | |
RU2697090C1 (ru) | Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf | |
JP3351748B2 (ja) | 2,3−ジ置換−(5,6)−ヘテロアリール縮合−ピリミジン−4−オンの新規なアトロプ異性体 | |
SK3192000A3 (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase | |
AU2004313486A1 (en) | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | |
KR100625379B1 (ko) | αLβ2 인테그린 매개된 세포 부착 저해제 | |
JP4109890B2 (ja) | 医薬組成物 | |
CA3176635A1 (en) | Bicyclic 1,4-diazepanones and therapeutic uses thereof | |
CN113754635A (zh) | 稠环类化合物及其制备方法和用途 | |
WO2004022554A1 (en) | Quinazolinone derivatives | |
RU2778478C2 (ru) | Бициклические производные дигидропиримидинкарбоксамида в качестве ингибиторов rho-киназы | |
AU2011236110B2 (en) | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | |
TWI250984B (en) | Inhibitors of alpha1beta2 mediated cell adhesion | |
AU2011236111B2 (en) | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | |
JP2004519435A (ja) | 抗炎症性薬物として有用なヒダントイン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020417 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20031125 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60019347 Country of ref document: DE Date of ref document: 20050512 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20050401159 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20050428 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KELLER & PARTNER PATENTANWAELTE AG |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1053473 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2240201 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
ET | Fr: translation filed | ||
26N | No opposition filed |
Effective date: 20060110 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20080924 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20081031 Year of fee payment: 9 Ref country code: DK Payment date: 20081013 Year of fee payment: 9 Ref country code: IE Payment date: 20081024 Year of fee payment: 9 Ref country code: LU Payment date: 20081031 Year of fee payment: 9 Ref country code: MC Payment date: 20081020 Year of fee payment: 9 Ref country code: NL Payment date: 20081015 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20081013 Year of fee payment: 9 Ref country code: FI Payment date: 20081014 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20081022 Year of fee payment: 9 Ref country code: BE Payment date: 20081010 Year of fee payment: 9 Ref country code: CY Payment date: 20080909 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20080919 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20100419 |
|
BERE | Be: lapsed |
Owner name: *TANABE SEIYAKU CO. LTD Effective date: 20091031 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20100501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100501 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100419 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091019 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100504 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091019 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091020 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20140911 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20141015 Year of fee payment: 15 Ref country code: FR Payment date: 20141008 Year of fee payment: 15 Ref country code: DE Payment date: 20141014 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20141017 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60019347 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20151019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151019 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160503 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151019 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151102 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20161129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151020 |